Difference between revisions of "Team:TrinityCollegeDublin"
Marlenne94 (Talk | contribs) |
|||
| (20 intermediate revisions by 4 users not shown) | |||
| Line 10: | Line 10: | ||
<body> | <body> | ||
<div class="logo logoAnimation"><a href="https://2015.igem.org/Team:TrinityCollegeDublin"><img src= | <div class="logo logoAnimation"><a href="https://2015.igem.org/Team:TrinityCollegeDublin"><img src= | ||
| − | "https://static.igem.org/mediawiki/2015/8/8b/TrinityDublin15_LogoGIF.gif" width=" | + | "https://static.igem.org/mediawiki/2015/8/8b/TrinityDublin15_LogoGIF.gif" width="147"></a></div> |
<form> | <form> | ||
| Line 238: | Line 238: | ||
<div class="artemisininGIF fadeIn"><img src= | <div class="artemisininGIF fadeIn"><img src= | ||
"https://static.igem.org/mediawiki/2015/c/c6/TrinityDublin15_ArtemisininGIF.gif" | "https://static.igem.org/mediawiki/2015/c/c6/TrinityDublin15_ArtemisininGIF.gif" | ||
| − | width=" | + | width="70%"></div> |
<div class="standardMargin fadeIn centre"> | <div class="standardMargin fadeIn centre"> | ||
| − | <h1>E.artemisia</h1> | + | <h1 class="headingOne">E.artemisia</h1> |
<h2>Combating Malaria with Synthetic Biology</h2> | <h2>Combating Malaria with Synthetic Biology</h2> | ||
</div> | </div> | ||
| − | + | <br><br> | |
<div class="container fadeIn"> | <div class="container fadeIn"> | ||
| − | <div class="leftContainer"> | + | <div class="leftContainer"><br> |
| − | < | + | One of the deadliest diseases in human history, <b>malaria now claims over 600,000 lives a year</b>. |
| + | <br><br> | ||
| + | |||
| + | Our mission is to investigate the <b>production of affordable antimalarial drugs</b> by the means of synthetic biology. We are working with <b>artemisinic acid producing E.coli cells</b> obtained from Amyris, with the support of Zagaya. | ||
| + | |||
| + | <br><br><br> | ||
| + | We have constructed biobricks to take advantage of an <b>alternative pathway in artemesinin synthesis</b>. This pathway allows for the production of <b>dihydroartemisinic acid</b>, a direct precursor to artemisinin. | ||
| + | <br><br> | ||
| + | This method has the potential for larger and cheaper artemisinin production in the future. | ||
</div> | </div> | ||
| Line 255: | Line 263: | ||
</div> | </div> | ||
<div class="projectVideo fadeIn"> | <div class="projectVideo fadeIn"> | ||
| − | <embed src="https://static.igem.org/mediawiki/2015/d/d1/TrinityDublin15_ProjectIntroduction.mp4" width=" | + | <embed src="https://static.igem.org/mediawiki/2015/d/d1/TrinityDublin15_ProjectIntroduction.mp4" width="600" height="400" |
autostart="0" autoplay="0" autostart="false" autoplay="false"> | autostart="0" autoplay="0" autostart="false" autoplay="false"> | ||
</div> | </div> | ||
| Line 272: | Line 280: | ||
<div class=" fadeIn"> | <div class=" fadeIn"> | ||
| − | + | ||
</div> | </div> | ||
Latest revision as of 15:11, 26 October 2015
E.artemisia
Combating Malaria with Synthetic Biology
One of the deadliest diseases in human history, malaria now claims over 600,000 lives a year.
Our mission is to investigate the production of affordable antimalarial drugs by the means of synthetic biology. We are working with artemisinic acid producing E.coli cells obtained from Amyris, with the support of Zagaya.
We have constructed biobricks to take advantage of an alternative pathway in artemesinin synthesis. This pathway allows for the production of dihydroartemisinic acid, a direct precursor to artemisinin.
This method has the potential for larger and cheaper artemisinin production in the future.
